Table 2 Clinical characteristics of the patietns with IPF classifed according to the levels of IL-33 and TSLP

No.

28

28

22

22

Age (year)

63.5 (32–76)

67.3 (46–86)

62.5 (44–77)

62.0 (41–75)

Sex (male/female)

17/11

19/9

14 /8

13 /9

Smoking (CS/ES/NS)

7/9/12

7/8/13

2 /10 /10

10/2/7

Follow-up duration (years)

3.5 (2.28–5.53)

3.6 (2.1–5.45)

5.1 (1.6–7.2)

5.5 (2.9–7.6)

FVC (% pred.)

74.5 (61.8–84.8)

70.0 (61.5–81.8)

77.0 (65.0–86.0)

83.5 (65.5–93.0)

FEV1 (% pred.)

81.0 (75.0–100.0)

86.0 (77.0–81.8)

89.0 (79.0–102.5)

97.0 (79.5–106.3)

DLCO (% pred.)

66.0 (53.3–70.5)

46.0 (38.5–73.5)

50.0 (42.0–77.8)

68.0 (59.0–83.0)

dFVC (%)/year

−12.0 (−16.0–3.5)

−13.0 (−18.3– − 2.8)

−8.5 (−13.50– -5.75)

−10.0 (−23.5– − 0.5)

BAL total cell count (10⁴/mL)

11.27 ± 7.41

6.10 ± 1.99

5.59 ± 2.38

14.62 ± 6.07

Macrophages (10⁴/mL)

10.50 ± 6.52

5.60 ± 1.54

4.13 ± 1.25

11.19 ± 4.16

Neutrophils (10⁴/mL)

1.97 ± 1.14

1.34 ± 0.78

1.72 ± 0.92

0.47 ± 0.21

Eosinophils (10⁴/mL)

0.56 ± 0.47

0.53 ± 0.28

0.66 ± 0.42

0.12 ± 0.05

Lymphocytes (10⁴/mL)

0.43 ± 0.34

0.12 ± 0.05

0.15 ± 0.06

0.08 ± 0.28